Comparison

Biological comparison

This compares mechanisms and evidence profiles. It is not a ranking, a recommendation, or a safety assessment.

Adapalene only

  • Nuclear receptor transcription pathway
  • Keratinocyte differentiation

Shared pathways

  • No shared curated pathways

L-Ascorbic acid only

  • Collagen biosynthesis and modifying enzymes
  • Detoxification of reactive oxygen species
  • Melanin biosynthesis

Adapalene

C28H28O3 · Retinoid

Single human studyOne curated human study — the finding has not been independently repeated in this dataset.

Adapalene is a synthetic naphthoic-acid retinoid that binds retinoic acid receptors with relative selectivity for RAR-beta and RAR-gamma. It is regulated as a medicine in many jurisdictions and is included here for mechanistic context only.

Targets

  • Retinoic acid receptor beta (RARB)activates (high confidence)
  • Retinoic acid receptor gamma (RARG)activates (high confidence)
  • Toll-like receptor 2 (TLR2)modulates (low confidence)

L-Ascorbic acid

C6H8O6 · Antioxidant

Repeated (2 studies)Two independent human studies point the same way; more replication would strengthen this.

L-ascorbic acid is vitamin C: a water-soluble reducing agent and an essential cofactor for the prolyl and lysyl hydroxylases that mature collagen.

Targets

  • Prolyl 4-hydroxylase subunit alpha-1 (P4HA1)activates (high confidence)
  • Procollagen-lysine 5-dioxygenase (PLOD1)activates (high confidence)
  • Tyrosinase (TYR)inhibits (low confidence)
  • Sodium-dependent vitamin C transporter 2 (SLC23A2)targets (medium confidence)

Evidence engine

Limited

Mostly mechanistic, animal or single-study evidence.

Skinceptor Evidence Index

44

experimental · of 100

This index is a research-navigation aid describing how much evidence exists and how it was produced. It is not a medical safety score, an efficacy guarantee, or a clinical recommendation.

Study composition

  • Randomised controlled trial1
  • In-vitro1
Total studies
2
Human studies
1
Largest sample
297
Range
1996–1998

Index breakdown

  • Study design quality57% × 28%

    Mean design weight across curated studies (meta-analysis 1.0, RCT 0.9, other human 0.7, review 0.45, animal 0.35, in-vitro 0.25).

  • Human evidence share33% × 22%

    Proportion of curated evidence measured in people rather than cells or animals.

  • Evidence volume50% × 14%

    Log-scaled count of curated studies, so volume alone cannot dominate the score.

  • Largest sample size82% × 12%

    Log-scaled largest reported sample size across curated human studies.

  • Replication33% × 12%

    Independent human studies, capped at three; one study is never treated as replicated.

  • Recency0% × 7%

    Linear decay over a twenty-year window from the most recent curated publication.

  • Source traceability0% × 5%

    Share of curated studies with a verified PMID or DOI in this dataset.

How is this determined? →

Insufficient comparable evidence for quantitative synthesis.

Evidence engine

Moderate

Some human evidence exists, but replication or sample sizes are limited.

Skinceptor Evidence Index

58

experimental · of 100

This index is a research-navigation aid describing how much evidence exists and how it was produced. It is not a medical safety score, an efficacy guarantee, or a clinical recommendation.

Study composition

  • Human1
  • Randomised controlled trial1
  • In-vitro3
  • Review2
Total studies
7
Human studies
2
Largest sample
19
Range
1991–2020

Index breakdown

  • Study design quality46% × 28%

    Mean design weight across curated studies (meta-analysis 1.0, RCT 0.9, other human 0.7, review 0.45, animal 0.35, in-vitro 0.25).

  • Human evidence share57% × 22%

    Proportion of curated evidence measured in people rather than cells or animals.

  • Evidence volume95% × 14%

    Log-scaled count of curated studies, so volume alone cannot dominate the score.

  • Largest sample size43% × 12%

    Log-scaled largest reported sample size across curated human studies.

  • Replication67% × 12%

    Independent human studies, capped at three; one study is never treated as replicated.

  • Recency70% × 7%

    Linear decay over a twenty-year window from the most recent curated publication.

  • Source traceability14% × 5%

    Share of curated studies with a verified PMID or DOI in this dataset.

How is this determined? →

Insufficient comparable evidence for quantitative synthesis.